- Organovo, a human tissue-engineering company, is on its way to launch the first 3-D bioprinted liver assay before the end of 2014.
- The market potential of the liver and kidney assays combined is in the billions.
- There are number of competitors emerging, but Organovo has a strong foothold.
- The stock comes with multiple risks, the major one being its volatility, but the profit potential is high.
- The current low price is a good entry point to go long on the stock.